Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck must face trial on a Black IT director’s claims that racial bias drove his firing after he ordered the removal of a White contractor from a project, a New York federal judge ruled.

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $98.28 which represents a slight increase of $0.83 or 0.85% from the prior close of $97.45. The stock opened at $97.42 and touched a ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price ...

Disclosed in the latest SEC filing, a significant insider purchase on January 29, involves Chirfi Guindo, Chief Marketing Officer at Merck & Co MRK.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...